BLB-202

BLB-202 is a preclinical-stage targeted protein degrader (TPD) developed by BayLink Biosciences for the treatment of solid tumors. It is designed to specifically target and induce the degradation of the Human Epidermal Growth Factor Receptor 2 (HER2) protein. Unlike traditional HER2-targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors that inhibit the signaling activity of the receptor, BLB-202 utilizes a degradation mechanism to eliminate the HER2 protein entirely from the cell. This approach aims to provide a more potent therapeutic effect and potentially overcome resistance mechanisms that often arise with conventional HER2-directed treatments in cancers such as breast and gastric tumors.